

Oklahoma Health Care Authority

Drug Utilization Review Board (DUR Board)

Meeting – October 14, 2015 @ 4:00 p.m.

Oklahoma Health Care Authority
4345 N. Lincoln Blvd.
Oklahoma City, Oklahoma 73105

AGENDA

Discussion and Action on the Following Items:

Items to be presented by Dr. Muchmore, Chairman:

1. Call To Order

- A. Roll Call – Dr. Cothran

Items to be presented by Dr. Muchmore, Chairman:

2. Public Comment Forum

- A. Acknowledgment of Speakers and Agenda Items

Items to be presented by Dr. Muchmore, Chairman:

3. Action Item – Approval of DUR Board Meeting Minutes – See Appendix A

- A. September 9, 2015 DUR Minutes – Vote
- B. September 9, 2015 DUR Recommendations Memorandum
- C. Veripred™ and Millipred™ Prior Authorization Memorandum
- D. Correspondence

Items to be presented by Dr. Muchmore, Chairman:

4. Action Item – Vote on 2016 Meeting Dates – See Appendix B

- A. 2016 DUR Board Meeting Dates – Vote

Items to be presented by Dr. Holderread, Dr. Muchmore, Chairman:

5. Update on Medication Coverage Authorization Unit/Bowel Preparation Medication Post-Educational Mailing – See Appendix C

- A. Medication Coverage Activity for September 2015
- B. Pharmacy Help Desk Activity for September 2015
- C. Bowel Preparation Medication Post-Educational Mailing

Items to be presented by Dr. Schmidt, Dr. Borders, Dr. Medina, Dr. Muchmore, Chairman:

6. Action Item – Vote to Prior Authorize Tykerb® (Lapatinib), Halaven® (Eribulin), Ixempra® (Ixabepilone), Kadcyla® (Ado-Trastuzumab), Afinitor® (Everolimus), & Perjeta® (Pertuzumab) – See Appendix D

- A. Recommendations

Items to be presented by Dr. Teel, Dr. Muchmore, Chairman:

7. Action Item – Vote to Prior Authorize Orkambi™ (Lumacaftor/Ivacaftor) – See Appendix E

- A. College of Pharmacy Recommendations

Items to be presented by Dr. Hsu, Dr. Muchmore, Chairman:

8. Action Item – Vote to Prior Authorize Savaysa® (Edoxaban) – See Appendix F

- A. College of Pharmacy Recommendations

Items to be presented by Dr. Adams, Dr. Muchmore, Chairman:

- 9. Action Item – Vote to Prior Authorize Epanova® (Omega-3-Carboxylic Acids), Praluent® (Alirocumab), & Repatha™ (Evolocumab) – See Appendix G**
- A. College of Pharmacy Recommendations
 - B. Attachment A: Diagnosis of Heterozygous Familial Hypercholesterolemia (HeFH)
 - C. Attachment B: Framingham Heart Study and Framingham Risk Score
 - D. Draft PCSK9 Inhibitor Prior Authorization Form

Items to be presented by Dr. Adams, Dr. Muchmore, Chairman:

- 10. Annual Review of Constipation and Diarrhea Medications and 30-Day Notice to Prior Authorize Movantik™ (Naloxegol), Viberzi™ (Eluxadoline), & Xifaxan® (Rifaximin) – See Appendix H**
- A. Current Prior Authorization Criteria
 - B. Utilization of Constipation and Diarrhea Medications
 - C. Prior Authorization of Constipation and Diarrhea Medications
 - D. Market News and Updates
 - E. Product Summaries
 - F. College of Pharmacy Recommendations
 - G. Utilization Details of Constipation and Diarrhea Medications

Items to be presented by Dr. Adams, Dr. Muchmore, Chairman:

- 11. 30-Day Notice to Prior Authorize Daraprim® (Pyrimethamine) – See Appendix I**
- A. Toxoplasmosis Background Information
 - B. Daraprim® (Pyrimethamine) Product Summary
 - C. Daraprim® (Pyrimethamine) Cost Update
 - D. Utilization Details of Daraprim® (Pyrimethamine)
 - E. College of Pharmacy Recommendations

Items to be presented by Dr. Teel, Dr. Muchmore, Chairman:

- 12. Annual Review of Allergy Immunotherapies and 30-Day Notice to Prior Authorize Oralair® (Sweet Vernal, Orchard, Perennial Rye, Timothy, & Kentucky Blue Grass Mixed Pollens Allergen Extract) – See Appendix J**
- A. Current Prior Authorization Criteria
 - B. Prior Authorization of Allergy Immunotherapies
 - C. Oralair® (Allergen Extract) Product Summary
 - D. College of Pharmacy Recommendations

Items to be presented by Dr. Hsu, Dr. Muchmore, Chairman:

- 13. Annual Review of Non-Steroidal Anti-Inflammatory Drugs and 30-Day Notice to Prior Authorize Dyloject™ (Diclofenac Sodium) – See Appendix K**
- A. Current Prior Authorization Criteria
 - B. Utilization of Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)
 - C. Prior Authorization of NSAIDs
 - D. Market News and Updates
 - E. Dyloject™ (Diclofenac Sodium) Product Summary
 - F. NSAID Price Trends
 - G. College of Pharmacy Recommendations
 - H. Utilization Details of NSAIDs

Items to be presented by Dr. Holderread, Dr. Muchmore, Chairman:

- 14. Annual Review of Targeted Immunomodulator Agents and 30-Day Notice to Prior Authorize Cosentyx® (Secukinumab) – See Appendix L**
- A. Current Prior Authorization Criteria
 - B. Utilization of Targeted Immunomodulator Agents
 - C. Prior Authorization of Targeted Immunomodulator Agents
 - D. Market News and Updates

- E. Cosentyx® (Secukinumab) Product Summary
- F. Hidradenitis Suppurativa Summary
- G. College of Pharmacy Recommendations
- H. Utilization Details of Targeted Immunomodulator Agents

Items to be presented by Dr. Holderread, Dr. Muchmore, Chairman:

15. Annual Review of Inhaled Tobramycin Products and Pulmozyme® (Dornase Alfa) and 30-Day Notice to Prior Authorize Cayston® (Aztreonam Inhalation) & Kitabis™ Pak (Tobramycin Inhalation) – See Appendix M

- A. Introduction
- B. Current Prior Authorization Criteria
- C. Utilization of Inhaled Tobramycin Products, Dornase Alfa, & Aztreonam Inhalation
- D. Prior Authorization of Inhaled Tobramycin Products and Dornase Alfa
- E. Market News and Updates
- F. Product Summaries
- G. College of Pharmacy Recommendations
- H. Utilization Details of Inhaled Tobramycin Products, Dornase Alfa, & Aztreonam Inhalation

Non-Presentation, Questions Only:

16. Annual Review of Xolair® (Omalizumab) – See Appendix N

- A. Current Prior Authorization Criteria
- B. Utilization of Xolair® (Omalizumab)
- C. Prior Authorization of Xolair® (Omalizumab)
- D. Market News and Updates
- E. College of Pharmacy Recommendations

Items to be presented by Dr. Keast, Dr. Muchmore, Chairman:

17. FDA and DEA Updates – See Appendix O

Items to be presented by Dr. Holderread, Dr. Muchmore, Chairman:

18. Future Business* (Upcoming Product and Class Reviews)

- A. Ophthalmic Anti-Inflammatories/Omidria™ (Phenylephrine/Ketorolac Injection)
- B. Topical Corticosteroids
- C. Xiaflex® (Collagenase Clostridium Histolyticum)
- D. Xgeva® (Denosumab)
- E. Erythropoietin Stimulating Agents
- F. Prialt® (Ziconotide)
- G. Tetracycline and Ofloxacin 400mg Tablets
- H. Keveyis™ (Dichlorophenamide)
- I. Ibrance® (Palbociclib)

**Future business subject to change.*

Items to be presented by Dr. Muchmore, Chairman:

19. Adjournment